Chalasani N - Search Results

1

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.

Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, Fontana RJ, Hayashi PH; US Drug-Induced Liver Injury Network. Rockey DC, et al. Among authors: chalasani n. Hepatology. 2010 Jun;51(6):2117-26. doi: 10.1002/hep.23577. Hepatology. 2010. PMID: 20512999 Free PMC article.

2

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.

Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC; Pegasys Transplant Study Group. Chalasani N, et al. Hepatology. 2005 Feb;41(2):289-98. doi: 10.1002/hep.20560. Hepatology. 2005. PMID: 15660392 Clinical Trial.

3

Statins and hepatotoxicity: focus on patients with fatty liver.

Chalasani N. Chalasani N. Hepatology. 2005 Apr;41(4):690-5. doi: 10.1002/hep.20671. Hepatology. 2005. PMID: 15789367 Review. No abstract available.

4

Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals.

Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Lammert C, et al. Among authors: chalasani n. Hepatology. 2008 Jun;47(6):2003-9. doi: 10.1002/hep.22272. Hepatology. 2008. PMID: 18454504

5

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Chalasani N, et al. Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4. doi: 10.1053/j.gastro.2008.09.011. Epub 2008 Sep 17. Gastroenterology. 2008. PMID: 18955056 Free PMC article.

6

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group. Fontana RJ, et al. Among authors: chalasani n. Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005. Drug Saf. 2009. PMID: 19132805 Free PMC article. Clinical Trial.

7

Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network.

David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group. David K, et al. Hepatology. 2009 Jun;49(6):1904-12. doi: 10.1002/hep.22868. Hepatology. 2009. PMID: 19434741 Free PMC article.

8

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events.

Lammert C, Bjornsson E, Niklasson A, Chalasani N. Lammert C, et al. Among authors: chalasani n. Hepatology. 2010 Feb;51(2):615-20. doi: 10.1002/hep.23317. Hepatology. 2010. PMID: 19839004

9

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM; Nonalcoholic Steatohepatitis Clinical Research Network. Abdelmalek MF, et al. Hepatology. 2010 Jun;51(6):1961-71. doi: 10.1002/hep.23535. Hepatology. 2010. PMID: 20301112 Free PMC article.

10

Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Neuschwander-Tetri BA, et al. Among authors: chalasani n. Hepatology. 2010 Sep;52(3):913-24. doi: 10.1002/hep.23784. Hepatology. 2010. PMID: 20648476 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

556 results

Search Page